A Randomized, Double Blind, Parallel-Group Comparison Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia.
Phase of Trial: Phase II
Latest Information Update: 24 May 2016
At a glance
- Drugs Donepezil (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eisai Inc
- 10 Jun 2017 Biomarkers information updated
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.